Retatrutide 20mg
Triple agonist (GIP/GLP‑1/glucagon receptors) investigated in obesity and metabolic‑disease research.
Research use only. Not for human or veterinary use.
-
Australia Wide Shipping
-
Delivers in: 3-7 Working Days Shipping & Return
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors[1], studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes[2][3]. With an extended half-life of approximately 6 days, this peptide enables convenient once-weekly subcutaneous dosing with a gradual titration protocol to optimize tolerability[1][4].
- Reconstitute: Add 2.0 mL bacteriostatic water → 10.0 mg/mL concentration for optimal weekly doses.
- Typical weekly range: 2–12 mg once weekly (gradual escalation over 12+ weeks).
- Easy measuring: At 10.0 mg/mL, 1 unit = 0.01 mL ≈ 100 mcg on a U-100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 2–4 weeks.
Technical Specifications:
Synonyms: LY3437943
Chemical Formula: C₂₄H₃₄Cl₂N₆O₄
CAS Number: 2381089-83-2
Molecular Weight: Approx. 5,534 g/mol
Purity: ≥99.0% (validated by Certificate of Analysis)
Appearance: White to off-white lyophilized powder
Peptide Length: 39 amino acids
Solubility: Fully soluble in water (H₂O)
Quality Verification: Confirmed by RP-HPLC analysis
Storage Conditions: Store dry at 2–8 °C; reconstituted material refrigerated and used within 6 weeks
Source: https://peptidedosages.com/single-peptide-dosages/retatrutide-20-mg-vial-dosage-protocol/
Research Use Only: Not for human or veterinary use.
| Strength | 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 50 mg |
|---|---|
| Pack size | 1 vial, 2 vials, 3 vials |









